On June 25, 2014, Nature’s Sunshine’s CEO, Greg Probert, signed a contract with Fusun Pharma, a $1.5 billion leading healthcare company in the People’s Republic of China, to form a joint venture to market and distribute Nature’s Sunshine and Synergy products in China. Mr. Probert will be CEO of this joint venture. This joint venture is the first of its kind between a U.S. company and a Chinese company for direct selling products in China. NSP products will now be available in 49 countries.
One unique feature of the market in China with regard to direct selling is that it is a “closed” market and does not allow up-line commissions to be paid outside of China. NSP products will be sold at Retail; Synergy products will sell at Distributor/Wholesale cost, according to a marketing plan to be developed.
Now is the prime time to invest in NSP stock. Its cost per share has already grown and should continue to escalate. It is anticipated that the closing on this venture will occur in the third quarter of 2014, after all the customary closing conditions and regulatory approvals are met and received.